Appili Therapeutics (OTCMKTS:APLIF) Releases Earnings Results

Appili Therapeutics (OTCMKTS:APLIF) announced its earnings results on Thursday. The company reported ($0.01) EPS for the quarter, Zacks reports.

Appili Therapeutics Price Performance

OTCMKTS APLIF remained flat at $0.02 on Friday. Appili Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.03. The stock has a market cap of $2.16 million, a PE ratio of -0.89 and a beta of -0.31. The firm’s fifty day simple moving average is $0.02 and its 200 day simple moving average is $0.01.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.